

Antibiotic Susceptibility of Common Organisms

2022 STHS McAllen - All Units

Numbers indicate percent susceptible; only the first isolate per patient per period is included

| SOUTH TEXAS HEALTH SYSTEM® | | # of Isolates | Beta-Lactams | | | | | | | FQ | AGs | | | Miscellaneous | | | | Urine Isolates Only | | | | | | | | | | |
|----------------------------|---|---------------|--------------|-------------------------|----------------------|-------------------------|-----------|-------------|----------|-----------|---------------|----------|------------|---------------|-------------|---------------------------|-------------------|---------------------|-----------|---------------|-------------------------------------|-----------------------------|---------------|------------|-------------------|---|---|---|
| | | | Oxacillin | Ampicillin ¹ | Ampicillin/Sulbactam | Piperacillin/Tazobactam | Cefazolin | Ceftriaxone | Cefepime | Meropenem | Ciprofloxacin | Amikacin | Gentamicin | Tobramycin | Clindamycin | Tetracycline ³ | TMP/SMX (Bactrim) | Vancomycin | Linezolid | # of Isolates | 1st Gen. Cephis (oral) ⁴ | Nitrofurantoin ⁵ | Ciprofloxacin | Ampicillin | TMP/SMX (Bactrim) | | | |
| Gram-Negative | <i>Acinetobacter baumannii</i> | 77 | - | - | 32 | 31 | - | - | 32 | 35 | 31 | - | 39 | 39 | - | - | 81 | - | - | - | - | - | - | - | - | - | - | - |
| | <i>Citrobacter freundii</i> ⁴ | 29 | - | - | - | 76 | - | - | 97 | 97 | 90 | 100 | 86 | 86 | - | - | 69 | - | - | - | - | - | - | - | - | - | - | - |
| | <i>Citrobacter koseri</i> ⁴ | 29 | - | - | - | 100 | 90 | 93 | 93 | 100 | 100 | 100 | 100 | 100 | - | - | 100 | - | - | - | - | - | - | - | - | - | - | - |
| | <i>Enterobacter cloacae</i> ⁶ | 139 | - | - | - | 71 | - | - | 94 | 98 | 93 | 100 | 94 | 92 | - | - | 84 | - | - | 51 | - | - | 92 | - | 80 | - | - | - |
| | <i>Escherichia coli</i> | 1910 | - | 33 | 51 | 92 | 72 | 74 | 74 | 100 | 61 | 100 | 80 | 76 | - | - | 57 | - | - | 1471 | 73 | 96 | 62 | 35 | 58 | - | - | - |
| | <i>Klebsiella aerogenes</i> ⁷ | 85 | - | - | - | 58 | - | - | 88 | 93 | 89 | 100 | 93 | 92 | - | - | 80 | - | - | - | - | 88 | - | 75 | - | - | - | - |
| | <i>Klebsiella oxytoca</i> | 66 | - | 0 | 58 | 89 | 68 | 74 | 76 | 100 | 88 | 100 | 76 | 73 | - | - | 68 | - | - | - | - | - | - | - | - | - | - | - |
| | <i>Klebsiella pneumoniae</i> | 654 | - | 0 | 57 | 83 | 64 | 65 | 66 | 94 | 81 | 98 | 81 | 79 | - | - | 66 | - | - | 390 | - | 27 | 83 | 0 | 71 | - | - | - |
| | <i>Morganella morganii</i> | 26 | - | 0 | 12 | 100 | - | 100 | 100 | 100 | 81 | 100 | 73 | 77 | - | - | 73 | - | - | - | - | - | - | - | - | - | - | - |
| | <i>Proteus mirabilis</i> | 375 | - | 60 | 79 | 99 | 93 | 98 | 99 | 100 | 83 | 100 | 88 | 87 | - | - | 75 | - | - | 218 | 93 | 0 | 87 | 62 | - | - | - | - |
| | <i>Pseudomonas aeruginosa</i> | 464 | - | - | - | 83 | - | - | 86 | 84 | 82 | 96 | 91 | 96 | - | - | - | - | 118 | - | - | 82 | - | - | - | - | - | - |
| | <i>Serratia marcescens</i> | 66 | - | - | - | 100 | - | 98 | 98 | 100 | 95 | 100 | 100 | 89 | - | - | 100 | - | - | - | - | - | - | - | - | - | - | - |
| | <i>Stenotrophomonas</i> ⁴ | 27 | - | - | - | 85 | - | - | - | - | - | - | - | - | - | - | 96 | - | - | - | - | - | - | - | - | - | - | - |
| Gram Positive | <i>Staphylococcus aureus</i> ^{8,9} | 607 | 63 | - | - | - | - | - | - | - | - | 92 | - | 75 | 89 | 93 | 100 | 100 | 53 | - | 100 | - | - | 91 | - | - | - | |
| | <i>Staphylococcus epidermidis</i> | 158 | - | - | - | - | - | - | - | - | - | 81 | - | 49 | 80 | 72 | 100 | 100 | - | - | - | - | - | - | - | - | - | - |
| | <i>Staphylococcus hominis</i> | 60 | - | - | - | - | - | - | - | - | - | 95 | - | 57 | 50 | 65 | 100 | 100 | - | - | - | - | - | - | - | - | - | - |
| | <i>Enterococcus faecalis</i> | 404 | - | 100 | - | - | - | - | - | - | - | - | - | - | 24 | - | 98 | 97 | 217 | - | 99 | - | 100 | - | - | - | - | - |
| | <i>Enterococcus faecium</i> ⁹ | 64 | - | 8 | - | - | - | - | - | - | - | - | - | - | 13 | - | 42 | 94 | - | - | - | - | - | - | - | - | - | - |

Resistance Rates: 37% MRSA, 10% VRE, 26% ESBL

¹ Ampicillin susceptibility indicates susceptibility to amoxicillin, amoxicillin-clavulanate, ampicillin-sulbactam, and piperacillin-tazobactam

² Aztreonam use is reserved for severe penicillin allergy (e.g. anaphylaxis); caution: may cross-react with ceftazidime allergy

³ Tetracycline susceptibility indicates susceptibility to doxycycline and minocycline; some organisms resistant to tetracycline may be susceptible to doxycycline or minocycline

⁴ When used for therapy of uncomplicated UTIs due to *E. coli*, *K. pneumoniae*, and *P. mirabilis*, cefazolin susceptibility indicates susceptibility to the oral agents cefaclor, cefdinir, cefpodoxime, cefprozil, cefuroxime axetil, and cephalexin

⁵ Nitrofurantoin is indicated for use in cystitis only; it should not be used for systemic infections, including pyelonephritis

⁶ Use of 3rd generation cephalosporins is not recommended; these organisms frequently become resistant during therapy

⁷ Formerly known as *Enterobacter aerogenes*

⁸ Oxacillin and cefazolin are considered first-line antibiotic therapies for MSSA

⁹ For staphylococci that test susceptible, aminoglycosides must be used in combination with beta-lactams or vancomycin for synergy

⁴ Susceptibility rates determined on small sample size (<30) and may be statistically unreliable; interpret with caution